BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 23532738)

  • 1. Androgen deprivation and androgen receptor competition by bicalutamide induce autophagy of hormone-resistant prostate cancer cells and confer resistance to apoptosis.
    Boutin B; Tajeddine N; Vandersmissen P; Zanou N; Van Schoor M; Mondin L; Courtoy PJ; Tombal B; Gailly P
    Prostate; 2013 Jul; 73(10):1090-102. PubMed ID: 23532738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.
    Thomas C; Wafa LA; Lamoureux F; Cheng H; Fazli L; Gleave ME; Rennie PS
    Prostate; 2012 Jun; 72(8):875-85. PubMed ID: 22072572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells.
    Quéro L; Giocanti N; Hennequin C; Favaudon V
    Prostate; 2010 Mar; 70(4):401-11. PubMed ID: 19902473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells.
    Gravina GL; Festuccia C; Millimaggi D; Dolo V; Tombolini V; de Vito M; Vicentini C; Bologna M
    Prostate; 2008 May; 68(7):793-801. PubMed ID: 18324645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased resistance to trail-induced apoptosis in prostate cancer cells selected in the presence of bicalutamide.
    Mitterberger M; Neuwirt H; Cavarretta IT; Hobisch A; Culig Z
    Prostate; 2007 Aug; 67(11):1194-201. PubMed ID: 17520660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
    Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
    Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
    Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
    Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autophagy regulates lipolysis and cell survival through lipid droplet degradation in androgen-sensitive prostate cancer cells.
    Kaini RR; Sillerud LO; Zhaorigetu S; Hu CA
    Prostate; 2012 Sep; 72(13):1412-22. PubMed ID: 22294520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AT-101 (R-(-)-gossypol acetic acid) enhances the effectiveness of androgen deprivation therapy in the VCaP prostate cancer model.
    McGregor N; Patel L; Craig M; Weidner S; Wang S; Pienta KJ
    J Cell Biochem; 2010 Aug; 110(5):1187-94. PubMed ID: 20589722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential mechanisms of bicalutamide-induced apoptosis in prostate cell lines.
    Floyd MS; Teahan SJ; Fitzpatrick JM; Watson RW
    Prostate Cancer Prostatic Dis; 2009; 12(1):25-33. PubMed ID: 18475288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivo.
    Landriscina M; Bagalà C; Piscazzi A; Schinzari G; Quirino M; Fabiano A; Bianchetti S; Cassano A; Sica G; Barone C
    Prostate; 2009 May; 69(7):744-54. PubMed ID: 19152342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of bicalutamide sensitivity in prostate cancer cells by an epigenetic Puralpha-mediated decrease in androgen receptor levels.
    Liu X; Gomez-Pinillos A; Liu X; Johnson EM; Ferrari AC
    Prostate; 2010 Feb; 70(2):179-89. PubMed ID: 19790234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-Azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors.
    Gravina GL; Marampon F; Di Staso M; Bonfili P; Vitturini A; Jannini EA; Pestell RG; Tombolini V; Festuccia C
    Prostate; 2010 Aug; 70(11):1166-78. PubMed ID: 20333699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo effects of bicalutamide on the expression of TrkA and P75 neurotrophin receptors in prostate carcinoma.
    Festuccia C; Gravina GL; Muzi P; Pomante R; Ventura L; Ricevuto E; Vicentini C; Bologna M
    Prostate; 2007 Sep; 67(12):1255-64. PubMed ID: 17596848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the effect of the antiandrogen apalutamide (ARN-509) versus bicalutamide on the androgen receptor pathway in prostate cancer cell lines.
    Koukourakis MI; Kakouratos C; Kalamida D; Mitrakas A; Pouliliou S; Xanthopoulou E; Papadopoulou E; Fasoulaki V; Giatromanolaki A
    Anticancer Drugs; 2018 Apr; 29(4):323-333. PubMed ID: 29381490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishment and characterization of an androgen receptor-dependent, androgen-independent human prostate cancer cell line, LNCaP-CS10.
    Ishikura N; Kawata H; Nishimoto A; Nakamura R; Ishii N; Aoki Y
    Prostate; 2010 Apr; 70(5):457-66. PubMed ID: 19902465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor.
    Wang Y; Liu G; Tong D; Parmar H; Hasenmayer D; Yuan W; Zhang D; Jiang J
    Prostate; 2015 Aug; 75(11):1187-96. PubMed ID: 25894097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigallocatechin-3-gallate and bicalutamide cause growth arrest and apoptosis in NRP-152 and NRP-154 prostate epithelial cells.
    Morrissey C; Brown M; O'Sullivan J; Weathered N; Watson RW; Tenniswood M
    Int J Urol; 2007 Jun; 14(6):545-51. PubMed ID: 17593102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do androgen deprivation drugs affect the immune cross-talk between mononuclear and prostate cancer cells?
    Salman H; Bergman M; Blumberger N; Djaldetti M; Bessler H
    Biomed Pharmacother; 2014 Feb; 68(1):21-4. PubMed ID: 24406295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The androgen receptor pathway is by-passed in prostate cancer cells generated after prolonged treatment with bicalutamide.
    Hobisch A; Fritzer A; Comuzzi B; Fiechtl M; Malinowska K; Steiner H; Bartsch G; Culig Z
    Prostate; 2006 Mar; 66(4):413-20. PubMed ID: 16302272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.